Overview

This trial is active, not recruiting.

Conditions ovarian cancer, sarcoma
Treatments cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, brachytherapy, intraoperative radiation therapy, radiation therapy
Sponsor Mayo Clinic
Collaborator National Cancer Institute (NCI)
Start date October 1991
End date September 2015
Trial size 120 participants
Trial identifier NCT00662233, 0791, 542-91, 919110, CDR0000582271, P30CA015083

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating patients with sarcoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Primary purpose treatment

Primary Outcomes

Measure
Efficacy in terms of long-term disease-free survival
time frame:
Clinical response of the tumors
time frame:
Pathologic response of the tumors
time frame:
Long term disease-free survival
time frame:

Eligibility Criteria

Male or female participants up to 21 years old.

DISEASE CHARACTERISTICS: - Diagnosis of any of the following: - High-grade nonmetastatic, nonrhabdomyosarcomatous soft tissue sarcomas (excluding undifferentiated sarcoma and Ewing sarcoma) - Small round cell sarcomas (excluding primitive neuroectodermal tumors of soft tissue) (closed to accrual) - Undifferentiated sarcomas (closed to accrual) - Rhabdomyosarcomas (excluding non-parameningeal head tumors, vaginal or stage I paratesticular) (closed to accrual) - All alveolar rhabdomyosarcomas (closed to accrual) - No evidence distant metastatic disease (i.e., lung, bone, bone marrow) - Local or regional nodal disease allowed - No spindle cell tumors of bone - Primary lesions do not have to be resectable PATIENT CHARACTERISTICS: - Creatinine ≤1.5 mg/dL OR creatinine clearance > 60 mL/min/ - AST/ALT < 2 times upper limit of normal (ULN) - Total bilirubin < 2 times ULN - LVEF ≥ 45% - No prior history of cancer - Not pregnant or nursing - Negative pregnancy test PRIOR CONCURRENT THERAPY: - Patients who have undergone radiation therapy after initial surgery are eligible but must have evaluation for metastatic disease within 2 weeks of starting chemotherapy - No prior chemotherapy

Additional Information

Official title A Pilot Study for Soft Tissue Sarcoma
Principal investigator Carola A. S. Arndt, MD
Description OBJECTIVES: - To evaluate the efficacy, in terms of clinical response, pathologic response, and long-term disease-free survival, of a multidrug chemotherapy regimen patients with spindle cell or small round cell sarcoma. OUTLINE: This is a multicenter study. - Induction therapy: Patients receive vincristine IV, cyclophosphamide IV over 1 hour and doxorubicin hydrochloride IV over 48 hours on day 1 in week 0. Patients continue to receive vincristine IV once weekly in weeks 1 and 2. Patients also receive etoposide IV over 1 hour and ifosfamide IV over 1 hour for 5 days in week 3. Treatment repeats every 6 weeks for 2 courses. - Local control: After completing induction therapy, patients are reevaluated for local control therapy. Some patients may undergo surgery and/or radiotherapy (e.g., brachytherapy, intraoperative radiotherapy, external beam therapy). Patients who undergo surgery begin consolidation therapy 2 weeks after completing surgery. Some patients undergo radiotherapy 5 days a week for 5½ weeks beginning at week 12 and/or after surgery (weeks 15-16). - Consolidation therapy: Patients receive vincristine IV, doxorubicin hydrochloride IV over 1 hour, and cyclophosphamide IV over 1 hour once in weeks 12 and 18*. Patients also receive etoposide IV over 1 hour and ifosfamide IV over 1 hour for 5 days in week 15. Patients are reevaluated for local control therapy at week 21. NOTE: *Patients undergoing radiotherapy do not receive doxorubicin hydrochloride in week 18 or week 24. - Maintenance therapy: Patient receive vincristine IV, doxorubicin hydrochloride IV over 1 hour, and cyclophosphamide IV over 1 hour once in week 24. Patients also receive etoposide IV over 1 hour and ifosfamide IV over 1 hour for 5 days in week 21. Treatment repeats every 6 weeks for 3 courses. In week 36, patients receive vincristine, doxorubicin hydrochloride and cyclophosphamide OR etoposide and ifosfamide as before. In week 39 patients receive etoposide and ifosfamide as before. After completion of treatment, patients are followed periodically for at least 5 years.
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by Mayo Clinic.